Further, 3-BP enhanced antitumor activity of daunorubicin (DNR) in breast cancer cells through monocarboxylate transporter 1 (MCT-1) (10), suggesting that 3-BP could be an effective therapeutic target for breast cancer treatment. The gene discussed is SLC16A1; the disease is breast carcinoma.